|D012213||Rheumatic Fever NIH||0.58|
|D001327||Autoimmune Diseases NIH||0.38|
|D012216||Rheumatic Diseases NIH||0.30|
There is one clinical trial.
To assess the safety and efficacy of CK0802 in treatment of patients with COVID-19 induced moderate-to-severe PNA-ARDS.
Description: Regimen related ≥ grade 3 toxicity within 48 hours of first infusion (DLT)Measure: Regimen related ≥ grade 3 toxicity within 48 hours of first infusion Time: 48 hours
Description: Alive and not intubated 28 days after the date of first infusionMeasure: 28-day treatment success, defined as S28 Time: 28 days
Description: Time to extubationMeasure: Time to extubation Time: 28 days
Description: Oxygenation requirement (PaO2/FiO2) change between day 0 and day +11Measure: Oxygenation improvement Time: 11 days
Description: Ventilator free days measured at day 28Measure: Ventilator free days Time: 28 days
Description: Organ failure free days measured at day 28Measure: Organ failure free days Time: 28 days
Description: ICU free days measured at day 28Measure: ICU free days Time: 28 days
Description: All-cause mortality at day 28Measure: All-cause mortality Time: 28 days
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports